SKOKIE, Ill.--(BUSINESS WIRE)--Apr. 1, 2019--
Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and
immunotherapeutic drugs utilizing spherical nucleic acid (SNA™)
constructs, announced today that its CEO, Dr. David Giljohann, will give
a company presentation on Monday, April 8, 2019 at 11:50 am GMT at the
H.C. Wainwright Global Life Sciences Conference. The presentation will
be made in the Stratton Suite of the Grosvenor House in London.
A live audio webcast will be available on the Investors section of
Exicure’s website: www.exicuretx.com.
The webcast will be archived for approximately 30 days following the
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company developing
therapeutics for immuno-oncology, inflammatory diseases and genetic
disorders based on our proprietary Spherical Nucleic Acid, or SNA
technology. We believe Exicure's proprietary SNA architecture has
distinct chemical and biological properties that may provide advantages
over other nucleic acid therapeutics and may have therapeutic potential
to target diseases not typically addressed with other nucleic acid
therapeutics. Exicure's lead program is in a Phase1b/2 trial in patients
with advanced solid tumors. Exicure is based outside of Chicago, IL.www.exicuretx.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190401005117/en/
Source: Exicure, Inc.